Self‐recognition of recurrences among patients with exudative age‐related macular degeneration

References

• Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age‐related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerie CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age‐related macular degeneration. Retina 2006; 26: 383–390.
   PubMed Web of Science ®Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography‐guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age‐related macular degeneration. Am J Ophthalmol 2007; 143: 566–583.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
   PubMed Web of Science ®Google Scholar
• You JY, Chung H, Kim HC. Evaluation of changes in choroidal neovascularization secondary to age‐related macular degeneration after anti‐VEGF therapy using spectral domain optical coherence tomography. Curr Eye Res 2012; 37: 438–445.
   PubMed Web of Science ®Google Scholar
• Schmid‐kubista KE, Krebs I, Ansari‐shahrezaei S, Haas P, Hagen S, Binder S. Comparing treatment of neovascular age‐related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono‐therapy‐‐a pilot study. Curr Eye Res 2011; 36: 958–963.
   Web of Science ®Google Scholar
• Moschos MM, Brouzas D, Chatziralli IP, Ladas I. Ranibizumab in the treatment of choroidal neovascularisation due to age‐related macular degeneration: an optical coherence tomography and multifocal electroretinography study. Clin Exp Optom 2011; 94: 268–275.
   PubMed Web of Science ®Google Scholar
• Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab‐treated neovascular age‐related macular degeneration; stratified by baseline vision. Clin Experiment Ophthalmol 2011; 39: 5–8.
   Web of Science ®Google Scholar
• Arias L, Armada F, Donate J, García‐arumí J, Giralt J, Pazos B et al. Delay in treating age‐related macular degeneration in Spain is associated with progressive vision loss. Eye (Lond) 2009; 23: 326–333.
   Web of Science ®Google Scholar
• Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S. Long‐term effects of ranibizumab treatment delay in neovascular age‐related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013; 251: 453–458.
   Web of Science ®Google Scholar
• Oliver‐fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age‐related macular degeneration. Can J Ophthalmol 2005; 40: 313–319.
   Web of Science ®Google Scholar
• Rauch R, Weingessel B, Maca SM, Vecsei‐marlovits PV. Time to first treatment: The significance of early treatment of exudative age‐related macular degeneration. Retina 2012; 32: 1260–1264.
   PubMed Web of Science ®Google Scholar
• Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age‐related macular degeneration: systematic review and meta‐analysis. Eye (Lond) 2014; 28: 788–796.
   PubMed Web of Science ®Google Scholar
• Loewenstein A, Ferencz JR, Lang Y, Yeshurun I, Pollack A, Siegal R et al. Toward earlier detection of choroidal neovascularization secondary to age‐related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina 2010; 30: 1058–1064.
   PubMed Web of Science ®Google Scholar
• Wang YZ, He YG, Mitzel G, Zhang S, Bartlett M. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci 2013; 54: 5497–5505.
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age‐related macular degeneration. The HOme Monitoring of the Eye (HOME) study design ‐ HOME Study report number 1. Contemp Clin Trials 2014; 37: 294–300.
   Web of Science ®Google Scholar
• Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem‐buffet S, Delshaye‐mazza C et al. Results of one‐year's treatment with ranibizumab for exudative age‐related macular degeneration in a clinical setting. Am J Ophthalmol 2009; 148: 409–413.
   PubMed Web of Science ®Google Scholar
• Koh V, Yang A, Saw SM, Chan YH, Lin ST, Tan MM et al. Differences in prevalence of refractive errors in young Asian males in Singapore between 1996–1997 and 2009–2010. Ophthalmic Epidemiol 2014; 21: 247–255.
   Web of Science ®Google Scholar
• He M, Huang W, Li Y, Zheng Y, Yin Q, Foster PJ. Refractive error and biometry in older Chinese adults: the Liwan eye study. Invest Ophthalmol Vis Sci 2009; 50: 5130–5136.
   PubMed Web of Science ®Google Scholar
• He M, Kong X, Chen Q, Zeng Y, Huang Y, Zhang J et al. Two‐year changes in refractive error and related biometric factors in an adult Chinese population. JAMA Ophthalmol 2014; 132: 978–984.
   Web of Science ®Google Scholar
• Tao Y, Jonas JB. Refractive error and smoking habits in exudative age‐related macular degeneration in a hospital‐based setting. Eye (Lond) 2010; 24: 648–652.
   Web of Science ®Google Scholar
• Lavanya R, Kawasaki R, Tay WT, Cheung GC, Mitchell P, Saw SM et al. Hyperopic refractive error and shorter axial length are associated with age‐related macular degeneration: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci 2010; 51: 6247–6252.
   Web of Science ®Google Scholar
• Hessellund A, Larsen DA, Bek T. The predictive value of subjective symptoms and clinical signs for the presence of treatment‐requiring exudative age‐related macular degeneration. Acta Ophthalmol 2012; 90: 471–475.
   Web of Science ®Google Scholar
• Fine SL. Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology 1985; 92: 603–609.
   Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and‐extend protocol. Ophthalmology 2015; 122: 146–152.
   PubMed Web of Science ®Google Scholar
• Engelbert M, Zweifel SA, Freund KB. Long‐term follow‐up for type 1 (subretinal pigment epithelium) neovascularization using a modified ‘treat and extend’ dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010; 30: 1368–1375.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen Qd, Kirchhof B et al. Intravitreal aflibercept (VEGF trap‐eye) in wet age‐related macular degeneration. Ophthalmology 2012; 119: 2537–2548.
   PubMed Web of Science ®Google Scholar
• Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 2006; 124: 193–198.
   PubMedGoogle Scholar